Avantor, Inc. (NYSE:AVTR) Shares Purchased by Ameriprise Financial Inc.

Ameriprise Financial Inc. raised its stake in shares of Avantor, Inc. (NYSE:AVTR - Free Report) by 15.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,645,022 shares of the company's stock after buying an additional 225,751 shares during the quarter. Ameriprise Financial Inc. owned about 0.24% of Avantor worth $34,661,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Perpetual Ltd grew its holdings in Avantor by 38.7% during the 4th quarter. Perpetual Ltd now owns 1,766,882 shares of the company's stock valued at $37,228,000 after buying an additional 493,408 shares in the last quarter. Rhumbline Advisers grew its holdings in Avantor by 1.8% during the 4th quarter. Rhumbline Advisers now owns 1,922,368 shares of the company's stock valued at $40,504,000 after buying an additional 33,692 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Avantor by 2.5% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 3,027,636 shares of the company's stock valued at $63,792,000 after buying an additional 74,735 shares in the last quarter. Blue Trust Inc. grew its holdings in Avantor by 6.9% during the 4th quarter. Blue Trust Inc. now owns 8,069 shares of the company's stock valued at $170,000 after buying an additional 522 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its holdings in Avantor by 38.1% during the 4th quarter. Robeco Institutional Asset Management B.V. now owns 119,063 shares of the company's stock valued at $2,509,000 after buying an additional 32,838 shares in the last quarter. 95.08% of the stock is owned by hedge funds and other institutional investors.

Avantor Stock Up 4.3%

Shares of AVTR stock traded up $0.56 on Friday, hitting $13.40. The stock had a trading volume of 22,017,022 shares, compared to its average volume of 7,794,817. The company has a quick ratio of 0.70, a current ratio of 1.07 and a debt-to-equity ratio of 0.54. The business has a 50 day moving average price of $14.76 and a 200 day moving average price of $18.56. The company has a market cap of $9.13 billion, a PE ratio of 12.88, a P/E/G ratio of 1.55 and a beta of 1.09. Avantor, Inc. has a one year low of $11.82 and a one year high of $28.00.

Avantor (NYSE:AVTR - Get Free Report) last released its quarterly earnings data on Friday, April 25th. The company reported $0.23 earnings per share for the quarter, meeting the consensus estimate of $0.23. The firm had revenue of $1.58 billion during the quarter, compared to the consensus estimate of $1.61 billion. Avantor had a return on equity of 12.17% and a net margin of 10.49%. The firm's quarterly revenue was down 5.9% on a year-over-year basis. During the same period in the previous year, the company posted $0.22 earnings per share. Research analysts anticipate that Avantor, Inc. will post 1.06 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Gregory L. Summe acquired 25,000 shares of the business's stock in a transaction dated Wednesday, May 7th. The shares were purchased at an average price of $12.00 per share, for a total transaction of $300,000.00. Following the completion of the acquisition, the director now directly owns 50,000 shares in the company, valued at $600,000. The trade was a 100.00% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Steven W. Eck sold 4,907 shares of the company's stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $17.53, for a total value of $86,019.71. Following the completion of the sale, the chief accounting officer now owns 40,604 shares in the company, valued at approximately $711,788.12. This represents a 10.78% decrease in their position. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms have recently commented on AVTR. The Goldman Sachs Group downgraded Avantor from a "buy" rating to a "neutral" rating and lowered their target price for the company from $23.00 to $14.00 in a research report on Tuesday, April 29th. Robert W. Baird lowered their price target on Avantor from $21.00 to $17.00 and set an "outperform" rating for the company in a research report on Monday, April 28th. Raymond James reissued an "outperform" rating and set a $24.00 target price (down from $26.00) on shares of Avantor in a research note on Monday, February 10th. TD Cowen lowered shares of Avantor from a "buy" rating to a "hold" rating and set a $15.50 target price for the company. in a research note on Monday, April 28th. Finally, Royal Bank of Canada lowered their target price on shares of Avantor from $24.00 to $20.00 and set an "outperform" rating for the company in a research note on Monday, April 28th. Seven research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $18.88.

Avantor Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.